Hepatitis B virus and hepatocellular carcinoma: antiviral therapy and risk estimation
10.3760/cma.j.issn.1673-4203.2012.12.017
- VernacularTitle:乙型肝炎病毒与肝细胞癌的抗病毒治疗与风险评估
- Author:
Chong WANG
;
Anyi QIAO
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Carcinoma,hepatocellular;
Antiviral therapy;
Risk estimation
- From:
International Journal of Surgery
2012;(12):846-848
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of hepatocellular carcinoma is increasing year by year all over the world.Hepatoma has become one of the main causes of cancer-related death.For many years,studies found the chronic hepatitis B virus infection is the leading cause of hepatocellular carcinoma,and antiviral therapy for hepatitis B virus could obviously reduce the incidence of hepatoma and prevent recurrence after hepatectomy.Making appropriate risk estimation in patients with chronic hepatitis B and providing patients with high risk the effective medical intervention can help to prevent the occurrence and delay the development of hepatocellular carcinoma.
